购物车
全部删除
您的购物车当前为空
别名 PR-957, ONX0914, ONX 0914
ONX-0914 (PR-957) 是选择性的低分子量多肽-7(LMP7)的抑制剂,LMP7 是免疫蛋白酶体的类糜蛋白酶亚单位。它是分枝杆菌蛋白酶体的非竞争性不可逆抑制剂,Ki 值为5.2 μM。它通过 HSF-1 介导的 p-TEFb 活化激活潜伏的 HIV-1。

ONX-0914 (PR-957) 是选择性的低分子量多肽-7(LMP7)的抑制剂,LMP7 是免疫蛋白酶体的类糜蛋白酶亚单位。它是分枝杆菌蛋白酶体的非竞争性不可逆抑制剂,Ki 值为5.2 μM。它通过 HSF-1 介导的 p-TEFb 活化激活潜伏的 HIV-1。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 532 | 现货 | |
| 5 mg | ¥ 1,230 | 现货 | |
| 10 mg | ¥ 1,920 | 现货 | |
| 25 mg | ¥ 3,980 | 现货 | |
| 50 mg | ¥ 5,680 | 现货 | |
| 100 mg | ¥ 7,920 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,590 | 现货 |
ONX-0914 相关产品
| 产品描述 | ONX-0914 (PR-957) is an effective and specific immunoproteasome inhibitor, which has minimal cross-reactivity for the constitutive proteasome. |
| 靶点活性 | Immunoproteasome:~10 nM |
| 体外活性 | PR-957通过选择性抑制LMP7, 阻断了活化单核细胞产生的白细胞介素-23(IL-23)以及T细胞产生的干扰素-γ和IL-2的生成。 |
| 体内活性 | 在类风湿性关节炎和红斑狼疮的小鼠模型中,ONX-0914的最大耐受剂量(MTD)为每千克体重30 mg/kg。 |
| 激酶实验 | 20 ng of purified human DDK is pre-incubated with increasing concentrations of each DDK inhibitor for 5 min. Then 10 μCi (γ)-32P ATP and 1.5 μM cold ATP are added in a buffer containing 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, and 1 mM DTT and incubated for 30 min at 30°C. The proteins are denatured in 1X Laemmli buffer at 100°C followed by SDS-PAGE and autoradiography on HyBlot CL film. Auto-phosphorylation of DDK is used as an indicator of its kinase activity. 32P-labeled bands are quantified using ImageJ and the IC50 values are calculated using GraphPad. |
| 别名 | PR-957, ONX0914, ONX 0914 |
| 分子量 | 580.67 |
| 分子式 | C31H40N4O7 |
| CAS No. | 960374-59-8 |
| Smiles | COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@@]2(C)CO2)cc1 |
| 密度 | no data available |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 50 mg/mL (86.11 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.44 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
评论内容